



Session	Start-ups/SMEs looking for Finance: Series A and Series B/C Funding
Title	OxFA — From Biogenic Residues to Formic Acid and Methanol
Company	OxFA GmbH
Speaker	Matthias Schmidt
TRL	TRL 4 - 7
Keywords feedstock (max 2)	Glycerin, Residues
Keywords technology (max 2)	catalysis, platformchemistry
Keywords End-Product (max 2)	Methanol, Formicacid
Abstract:	
OxFA has developed a patent-protected platform technology that converts biogenic residues — glycerin, C5 sugars, side streams from biomass fractioning, and residues from plastic recycling — into formic acid and methanol. The process has been validated in continuous pilot operation for >5,000 hours, with a proprietary catalyst and multiple patented process routes forming the core IP barrier. OxFA operates as a capital-light technology licensor and joint venture partner: partners build and operate the plants, while OxFA provides the license, catalyst, and technical support in return for upfront fees and recurring royalties. Formic acid is the near-term growth driver, with structural advantages over fossil production from EU carbon pricing and customers' Scope 3 reporting needs. A 5,000 t/a reference plant is currently under technical evaluation with a potential industrial partner — validating both the technology and the investment case for the licensing model at scale. Methanol is the platform's second growth stage: OxFA's route needs roughly one-third less hydrogen than conventional CO₂-based green methanol, improving its cost position as hydrogen prices fall and as FuelEU Maritime and related regulation raise the value of low-carbon methanol. OxFA is raising growth financing to scale its reference plants and licensing pipeline across both product lines.	